The Metastatic Castration-Resistant Prostate Cancer therapeutics market is anticipated to grow in the coming years owing to the increasing incidence, improvement in diagnosis methodologies, incremental healthcare spending across the globe, as well as treatment of mCRPC with the accessible novel therapies in the market. The pipeline of mCRPC is very robust, and some of the key players such as Astrazeneca, Takeda, Pfizer, Merck, Amgen, Bayer, Astellas Pharma, Bristol-Myers Squibb, Orion Pharmaceuticals at the global level are involved in developing therapies for mCRPC.
“Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metastatic Castration-Resistant Prostate Cancer Market.
The Metastatic Castration-Resistant Prostate Cancer Pipeline report embraces in-depth commercial, regulatory, and Metastatic Castration-Resistant Prostate Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Metastatic Castration-Resistant Prostate Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Metastatic Castration-Resistant Prostate Cancer treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Metastatic Castration-Resistant Prostate Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Metastatic Castration-Resistant Prostate Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Metastatic Castration-Resistant Prostate Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic Castration-Resistant Prostate Cancer therapeutic market.
Metastatic Castration-Resistant Prostate Cancer Therapeutics Landscape
There are approx. 75+ key companies developing therapies for Metastatic Castration-Resistant Prostate cancer. Currently, Clovis Oncology is leading the therapeutics market with its Metastatic Castration-Resistant Prostate cancer drug candidates in the most advanced stage of clinical development.
Metastatic Castration-Resistant Prostate Cancer Companies Actively Working in the Therapeutic Market Include:
-
Accutar Biotechnology Inc
-
Amgen
-
Astellas Pharma/Seagen
-
AstraZeneca
-
Bayer
-
Clovis Oncology
-
Dizal Pharmaceuticals
-
Eli Lilly and Company
-
Forma Therapeutics, Inc.
-
Hinova Pharmaceuticals
-
Lantern Pharma
-
Molecular Insight Pharmaceuticals
-
Pfizer
-
Progenics Pharmaceutical
-
Regeneron Pharmaceuticals
-
Surface Oncology
-
Taiho Oncology, Inc.
-
Veru Healthcare
-
Zenith Epigenetic
And many others
Emerging and Marketed Metastatic Castration-Resistant Prostate Cancer Drugs Covered in the Report Include:
-
AC0176: Accutar Biotechnology
-
Capivasertib: AstraZeneca
-
FT-7051: Forma Therapeutics
-
HB-300: Hookipa Pharma
-
HP518: Hinova Pharmaceuticals
-
JANX007: Janux Therapeutics
-
LAVA-1207: Lava Therapeutics
-
Onvansertib: Cardiff Oncology
-
PNT2002: POINT Biopharma
-
Rucaparib: Clovis Oncology
-
SRF617: Surface Oncology
-
TmPSMA-02: Tmunity Therapeutics
-
ZEN003694: Zenith Epigenetics
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Metastatic Castration-Resistant Prostate Cancer Companies Working in the Market @
Analysis of Emerging Metastatic Castration-Resistant Prostate Cancer Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Metastatic Castration-Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Intravenous
-
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
-
Small molecule
-
Cell Therapy
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
-
Proto-oncogene protein c-akt inhibitor
-
Ionizing radiation emitter
-
Programmed cell death-1 ligand-1 inhibitor
-
Androgen receptor antagonist
-
Bromodomain and extra terminal domain protein inhibitor
-
Polo-like kinase 1 inhibitor
-
Antibody-dependent cell cytotoxicity
-
1 Phosphatidylinositol 3 kinase inhibitor
-
Androgen receptor degradation enhancer
-
P300-CBP transcription factor inhibitor
-
Immunologic cytotoxicity
Learn How the Metastatic Castration-Resistant Prostate Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Metastatic Castration-Resistant Prostate Cancer Treatment Patterns
4. Metastatic Castration-Resistant Prostate Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Castration-Resistant Prostate Cancer Late Stage Products (Phase-III)
7. Metastatic Castration-Resistant Prostate Cancer Mid-Stage Products (Phase-II)
8. Metastatic Castration-Resistant Prostate Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Castration-Resistant Prostate Cancer Discontinued Products
13. Metastatic Castration-Resistant Prostate Cancer Product Profiles
14. Major Metastatic Castration-Resistant Prostate Cancer Companies in the Market
15. Key Products in the Metastatic Castration-Resistant Prostate Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. Metastatic Castration-Resistant Prostate Cancer Unmet Needs
18. Metastatic Castration-Resistant Prostate Cancer Future Perspectives
19. Metastatic Castration-Resistant Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Diverticulitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diverticulitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Diverticulitis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/